ArticleNaunyn-Schmiedeberg's archives of pharmacology2020
Synthesis, characterization, and biocompatibility of lanthanum titanate nanoparticles in albino mice in a sex-specific manner.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Systematic review of the osteogenic effect of rare earth nanomaterials and the underlying mechanisms.Journal of nanobiotechnology · 2024Pooled it
- Rare-Earth Elements at the Interface of Chemistry and Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Acute brain injury and nanomedicine: sex as a biological variable.Frontiers in biomaterials science · 2024Article
- Article
- Article
- Sex and Gender Dimensions in Hazard and Risk Assessment of Engineered Nanomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to report the synthesis, characterization, and biocompatibility of lanthanum titanate nanoparticles (LT NPs) in albino mice. Microemulsion method was used to generate LT NPs. Seven-week-old albino mice of both sexes orally received 50 mg/ml saline/kg body weight of nanoparticles for 15 days (group 1) and 29 days (group 2). Control groups were maintained in parallel. Selected behavioral (rotarod, light and dark box, open-field and Morris water maze) tests were conducted, blood biochemical analysis was done, and antioxidants were determined in vital organs of all treatments. Male mice treated with LT NPs for 15 days spent significantly more time in light and less time in dark during light dark box test. While they had made significantly more platform entries and platform maximum visits during acquisition phase of Morris water maze test, they remained unaffected in probe trail performance when compared with control. These male mice had significantly reduced white blood cells, lymphocyte, and monocyte count and significantly increased triglyceride levels in serum than the control group. They had higher level of superoxide dismutase (SOD) in heart and reduced level of malonaldehyde (MDA) in kidney while 15-day LT NP-treated females had significantly higher level of SOD in liver and kidney. Male mice treated with NPs for 29 days had increased anticlockwise rotations during open field, reduced level of triglycerides in serum, and significantly higher level of SOD in kidney and MDA in lungs. In contrast, female mice treated with NPs for 29 days had higher SOD level in liver, kidney, and heart than their control group. Oral supplementation of LT NPs for variable duration improved the exploratory behavior in male but disturbed blood chemistry and antioxidants from vital organs under both experimental conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.